Today: 20 May 2026
Bradesco stock price hovers near a 52-week high as Brazil rate decision nears, earnings next week
28 January 2026
2 mins read

Bradesco stock price hovers near a 52-week high as Brazil rate decision nears, earnings next week

New York, Jan 28, 2026, 11:23 (ET) — Regular session

  • Banco Bradesco’s shares on the U.S. market nudged up 0.1% in early trading, hovering close to their recent peaks
  • Brazil’s central bank is set to announce its policy decision Wednesday, following inflation figures that reached the upper limit of the target range
  • Bradesco will release its fourth-quarter results on Feb. 5, followed by a call scheduled for Feb. 6

Shares of Banco Bradesco S.A. listed in the U.S. edged up Wednesday, staying near a 52-week high. Investors held back ahead of Brazil’s interest-rate announcement scheduled for later and digested a flurry of company updates ahead of next week’s earnings.

This matters now because of rates. Brazilian banks often react to the Selic, the country’s key benchmark rate, since it influences loan demand, funding costs, and credit stress on household balance sheets.

This week’s focus centers on inflation figures and the central bank’s Copom policy committee kicking off its 2026 decisions. Traders are betting on a pause now, with rate cuts on the horizon. That uncertainty has left bank stocks jittery, despite a slow corporate news flow.

Bradesco’s ADRs changed hands at $4.145, edging up roughly 0.1%, following an earlier range between $4.135 and $4.20.

Shares of Brazil-linked financial rivals saw gains: Itaú Unibanco’s U.S.-listed stock climbed roughly 1.5%, Santander Brasil’s ADRs gained about 0.4%, and Nubank’s Nu Holdings moved slightly higher.

Brazil’s IPCA-15 inflation index, a key early gauge of official inflation, ticked up 0.20% in January. That lifted the annual rate to 4.50%, right at the top end of the central bank’s target band. The Copom meeting on Wednesday is widely expected to hold rates steady. Still, investors are eager for hints on whether rate cuts might begin as soon as March.

William Jackson, chief emerging markets economist at Capital Economics, said the 4.5% figure will probably “remove any lingering expectations” of a rate cut at this meeting, though he still anticipates easing to begin in March. Capital Economics

This week on Latibex in Madrid, Bradesco revised its tax rate and per-share net values for the monthly “interest on shareholders’ equity” — a Brazilian cash distribution akin to dividends — but left its payment timetable intact. latibex.com

The lender also announced its next annual general meeting is set for March 10.

Bradesco announced it has renewed its agreement with payments company Cielo. The deal, labeled a related-party transaction, involves services aimed at attracting and retaining merchants for possible accreditation within the Cielo system.

Bradesco bulls face a clear risk: should Copom take a hawkish turn beyond what investors anticipate—or if inflation picks up again—expect rate-cut bets to unravel quickly, dragging bank shares lower. Signs of rising provisions or deteriorating credit quality in Bradesco’s upcoming results would only intensify this pressure.

Attention is now on Wednesday’s central bank decision and Bradesco’s Q4 report, set for Feb. 5 after markets close in Brazil and New York. The bank will hold a management videoconference the next morning, Feb. 6, at 8:30 a.m. ET.

Stock Market Today

  • Roper Technologies (ROP) Trading Below Analyst Targets, Potentially Undervalued
    May 19, 2026, 11:35 PM EDT. Roper Technologies (ROP) shares fell about 9% in the past month to $328.91, with a 1-year total shareholder return down 42.68%, reflecting investor concerns over growth and risk balance. Analysts estimate a fair value around $453.75, implying the stock is 27.5% undervalued. This view hinges on Roper's continued growth via acquisitions and AI-driven software, supporting strong cash flow and EBITDA margin expansion. However, risks include potential integration challenges and rising competition. Investors are advised to carefully assess Roper's revenue trajectory, profit margins, and execution capabilities amid mixed market sentiment.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Commvault stock steadies premarket after 31% wipeout on ARR worries
Previous Story

Commvault stock steadies premarket after 31% wipeout on ARR worries

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop